Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WF10 in persistent allergic rhinitis
NCT01586468Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2010
- Primary completion
- Sep 2010
- Countries
- 1
- Sponsor
- Miravo Healthcare
- Modality
- Small Molecules
- Drugs
- tetrachlorodecaoxide
- Conditions
- allergic rhinitis (AR)
01
Overview
Phase 2, randomised, double-blind trial in allergic rhinitis (AR) comparing WF10 with Placebo (2 arms). Primary endpoint: Total Nasal Symptom Score at 9 weeks. Started Mar 2010; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
WF10
WF10 0.5 mL/kg IV daily for 5 days
Placebo
Saline solution IV daily for 5 days
03
Who it enrols
Adults with a history of persistent allergic rhinitis for at least 2 years and a positive allergen skin test, with a baseline TNSS >= 6.
04
Endpoints
Primary
Total Nasal Symptom Score
Secondary
Mini Rhinoconjunctivitis Quality of Life Questionnaire
Patient's Overall Health Assessment
Rhinometric parameters
Spirometric parameters
Beyond the preview
Go deeper on NCT01586468.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01586468.